Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, allowing for the removal of uremic toxins and excess fluid via ultrafiltration. The low magnesium concentration (0.25 mEq/L) helps prevent hypermagnesemia in patients with renal failure.
Removes waste products (e.g., urea, creatinine) and excess fluid from the blood through peritoneal dialysis by diffusion and osmosis across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Treatment of acute and chronic renal failureManagement of end-stage renal disease (ESRD)
Intraperitoneal administration: 2 L per exchange, 4 exchanges daily. Dextrose concentration (1.5%, 2.5%, or 4.25%) determined by ultrafiltration needs. Low magnesium formulation selected based on serum magnesium levels.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges daily; dwell time 4-6 hours; concentration selected based on ultrafiltration needs.
None Documented
None Documented
Intraperitoneal dextrose: absorption half-life ~1.5-2 hours; elimination of absorbed glucose follows endogenous glucose kinetics (t1/2 ~1-2 hours). Clinical note: Continuous dwell results in steady-state concentrations.
The terminal half-life of icodextrin (as total icodextrin-derived oligosaccharides) is approximately 5-8 hours after a single dwell, reflecting clearance from the plasma compartment. Clinically, sustained levels can occur with repeated exchanges.
Dextrose is metabolized via glycolysis and the citric acid cycle; magnesium is excreted renally and undergoes reabsorption in the kidneys; other electrolytes are regulated by renal function. No specific enzyme induction or inhibition noted.
Dextrose is metabolized via glycolysis; lactate is converted to bicarbonate in the liver. No significant hepatic metabolism for electrolyte components.
Primarily renal (peritoneal clearance): ~60-80% of glucose absorbed is metabolized; dextrose metabolites (CO2, water) excreted via lungs and kidneys. Magnesium and other electrolytes are removed via peritoneal dialysis; net elimination varies with dialysis prescription.
Delflex-LM with Dextrose 1.5% (icodextrin) is a peritoneal dialysis solution. Icodextrin is metabolized to oligosaccharides and primarily eliminated via the peritoneal cavity during dialysis. Renal excretion is minimal (<1%). The majority of icodextrin and its metabolites are removed with the dialysate effluent.
Dextrose: negligible binding. Magnesium: ~30% bound to albumin; Low Magnesium formulation minimizes magnesium load.
Icodextrin and its metabolites are minimally protein-bound (<5%), primarily to albumin.
Dextrose: Vd ~0.2-0.3 L/kg (total body water). Magnesium: Vd ~0.5-0.7 L/kg. Clinical meaning: Distributes into extracellular fluid; low Vd reflects limited tissue distribution.
The apparent volume of distribution (Vd) for icodextrin-derived oligosaccharides is approximately 0.1-0.2 L/kg, reflecting distribution mainly in the extracellular fluid and limited distribution into cells.
Intraperitoneal: dextrose absorption is 60-80% over a dwell; systemically bioavailable as absorbed glucose. Not applicable for IV or other routes.
Bioavailability: Not applicable for the intraperitoneal route (100% exposure to peritoneal cavity). For systemic absorption, 60-70% of the administered icodextrin dose is absorbed across the peritoneum into the systemic circulation during a dwell, but this is not a standard bioavailability measure.
No dose adjustment for renal impairment; drug is administered intraperitoneally for peritoneal dialysis. Monitor serum electrolytes and ultrafiltration.
No dose adjustment required for renal impairment as drug is administered intraperitoneally for peritoneal dialysis.
No specific adjustment; caution in hepatic impairment due to risk of lactate metabolism impairment with dextrose. Monitor serum lactate and electrolytes.
No specific pediatric dosing available; use adult dosing with caution and monitor for signs of fluid overload or electrolyte imbalance.
Weight-based: 30-40 mL/kg per exchange, 4-5 exchanges daily. Adjust dextrose concentration based on ultrafiltration target. Low magnesium product used if hypermagnesemia risk.
Individualized based on body weight: typical starting volume 30-40 mL/kg per exchange, 4-5 exchanges daily; adjust to achieve adequate ultrafiltration and solute clearance.
No specific dose adjustment; monitor fluid status, electrolytes, and ultrafiltration volume closely due to increased risk of volume overload and electrolyte disturbances.
Use same dosing as younger adults; monitor fluid and electrolyte status closely due to increased risk of fluid overload and electrolyte disturbances.
None
Not for intravenous use. Use only for intraperitoneal administration.
["Not for intravenous use","Risk of peritonitis","Electrolyte imbalance (hypokalemia, hypomagnesemia, hypocalcemia)","Fluid overload or dehydration","Hyperglycemia, especially in diabetic patients","Abdominal wall hernias","Ileus or mechanical obstruction","Encapsulating peritoneal sclerosis (rare)"]
["Monitor for peritonitis, electrolyte imbalances, and fluid overload","Use with caution in patients with severe hyperglycemia or lactic acidosis","Mechanical complications (e.g., catheter malfunction, leakage) may occur"]
["Pre-existing severe hypokalemia","Hypercalcemia","Severe hyperglycemia uncorrected","Significant abdominal adhesions or fibrosis","Pre-existing peritoneal diaphragmatic defects","History of severe pancreatitis or diverticulitis","Inability to perform dialysis exchanges safely"]
["Severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions or fibrosis compromising membrane function","Active intra-abdominal infection or peritonitis","Pre-existing severe lactic acidosis","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No direct food interactions with the solution itself, but dietary management is critical. Magnesium-restricted diet advised if serum magnesium is elevated; avoid high-magnesium foods like nuts, seeds, legumes, whole grains, chocolate, bananas, and dark leafy greens. Dextrose content may affect glycemic control; diabetic patients should monitor carbohydrate intake and adjust insulin as needed. Potassium and phosphorus restrictions may also apply based on individual lab values.
["Avoid foods high in potassium (e.g., bananas, oranges, potatoes, tomatoes) unless dietary potassium is restricted per renal diet.","Limit intake of phosphorus-rich foods (e.g., dairy, nuts, beans) to manage hyperphosphatemia.","Restrict sodium intake to control fluid retention and blood pressure as advised by renal diet.","Maintain adequate protein intake as prescribed, typically 1.2-1.5 g/kg/day.","Monitor fluid intake as per individual dry weight and ultrafiltration goals.","Avoid grapefruit juice as it may affect drug metabolism (relevant only if concomitant medications are affected)."]
Delflex with Dextrose 4.25% Low Magnesium is a peritoneal dialysis solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. In general, peritoneal dialysis may cause electrolyte disturbances and fluid shifts that could affect fetal well-being. Hyperglycemia from dextrose absorption may pose risks during organogenesis (first trimester) and later trimesters. Use only if clearly needed and monitor maternal glucose and electrolytes closely.
No known teratogenic effects in humans; intraperitoneal administration of dialysis solutions during pregnancy may cause maternal fluid and electrolyte disturbances that secondarily affect the fetus. Use only if clearly needed.
It is not known whether Delflex components are excreted in human milk. Dextrose is a normal constituent of milk. Calcium, magnesium, and sodium are present in milk and the additional amounts from dialysis are likely negligible. However, due to potential for systemic absorption of dextrose and electrolyte shifts, caution is advised. No M/P ratio is available.
Excreted into breast milk in negligible amounts; M/P ratio not established. Compatible with breastfeeding.
Dosing of peritoneal dialysis solution (volume, dwell time, number of exchanges) should be individualized based on maternal renal function, electrolyte status, and glycemic control. Pregnancy may require increased dialysis dose due to increased metabolic demands and volume of distribution. Monitor blood glucose closely as dextrose absorption can cause hyperglycemia; insulin adjustment may be necessary. No specific dose adjustment of the solution is defined; clinical judgment and frequent monitoring are required.
No specific dose adjustment recommended; monitor for volume overload and electrolyte imbalances due to increased plasma volume in pregnancy.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM is a peritoneal dialysis solution indicated for patients with end-stage renal disease (ESRD) to remove waste products and excess fluid via the peritoneal membrane. The low magnesium formulation (0.5 mEq/L) is specifically designed for patients at risk of hypermagnesemia, such as those with impaired renal function or on magnesium-containing medications. Monitor serum magnesium levels regularly; hypomagnesemia is also possible if dietary intake is insufficient. The 4.25% dextrose concentration provides the highest ultrafiltration capacity among standard solutions, making it suitable for fluid overload states. Use with caution in patients with severe hyperglycemia or glucose intolerance, as the dextrose load may elevate blood glucose. Ensure sterile technique during bag exchange to prevent peritonitis.
Continuous ambulatory peritoneal dialysis (CAPD) solution; verify glucose concentration (1.5%) and correct patient before use; warm to body temperature prior to instillation to reduce discomfort; check for cloudiness, discoloration, or leaks before administration; monitor effluent for clarity and volume; adjust dwell time based on ultrafiltration needs; use sterile technique for connection and disconnection.
Wash hands thoroughly before handling the dialysis bag or catheter site.Inspect the solution bag for cloudiness, discoloration, or leaks; do not use if present.Use only as directed by your healthcare provider about the number and duration of exchanges.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or abdominal pain, fever, or nausea.Monitor your blood glucose levels if you have diabetes, as the dextrose in the solution may raise blood sugar.Follow a kidney-friendly diet as recommended, which may include limiting certain foods high in magnesium (e.g., nuts, seeds, leafy greens) if your magnesium levels are high.Do not reuse the dialysis bag or tubing; dispose as instructed.Keep a log of your daily weight and report any rapid weight gain or persistent edema.Avoid vigorous exercise that could dislodge the catheter.Seek immediate medical attention if you experience shortness of breath, chest pain, or severe abdominal pain.
Wash hands thoroughly before handling the solution.Inspect the solution bag for any cloudiness, particles, or leaks before use; do not use if present.Warm the solution to body temperature by placing it on a warmer or using body heat, not in boiling water or microwave.Use strict sterile technique when connecting and disconnecting the solution to prevent infection.Record the volume of effluent drained and report any significant decrease or cloudy appearance to your healthcare provider.Follow the prescribed dwell time and exchange schedule exactly as directed.Do not reuse any of the solution or tubing; all components are for single use only.Store unused bags at room temperature away from direct sunlight and heat.